The present invention relates to novel 5,6-dihydro-2H-[1,4]oxazin-3-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimers disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Downs syndrome, dementia associated with stroke, dementia associated with Parkinsons disease and dementia associated with beta-amyloid.
